Your browser doesn't support javascript.
loading
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Sidders, Ben; Zhang, Pei; Goodwin, Kelly; O'Connor, Greg; Russell, Deanna L; Borodovsky, Alexandra; Armenia, Joshua; McEwen, Robert; Linghu, Bolan; Bendell, Johanna C; Bauer, Todd M; Patel, Manish R; Falchook, Gerald S; Merchant, Melinda; Pouliot, Gayle; Barrett, J Carl; Dry, Jonathan R; Woessner, Rich; Sachsenmeier, Kris.
Afiliación
  • Sidders B; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. benjamin.sidders@astrazeneca.com.
  • Zhang P; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Goodwin K; Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • O'Connor G; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Russell DL; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Borodovsky A; Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Armenia J; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • McEwen R; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Linghu B; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
  • Patel MR; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
  • Falchook GS; Sarah Cannon Research Institute/HealthONE, Denver, Colorado.
  • Merchant M; Early Clinical Development, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Pouliot G; Early Clinical Development, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Barrett JC; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Dry JR; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Woessner R; Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Sachsenmeier K; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
Clin Cancer Res ; 26(9): 2176-2187, 2020 05 01.
Article en En | MEDLINE | ID: mdl-31953314
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenosina / Antagonistas del Receptor de Adenosina A2 / Inmunoterapia / Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenosina / Antagonistas del Receptor de Adenosina A2 / Inmunoterapia / Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido